SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-18-059914
Filing Date
2018-11-14
Accepted
2018-11-14 16:03:19
Documents
56
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tv506160_10q.htm 10-Q 413488
2 EXHIBIT 31.1 tv506160_ex31-1.htm EX-31.1 10586
3 EXHIBIT 32.1 tv506160_ex32-1.htm EX-32.1 4704
  Complete submission text file 0001144204-18-059914.txt   5036248

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT ttnp-20180930.xml EX-101.INS 1498860
5 XBRL TAXONOMY EXTENSION SCHEMA ttnp-20180930.xsd EX-101.SCH 36360
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ttnp-20180930_cal.xml EX-101.CAL 29576
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ttnp-20180930_def.xml EX-101.DEF 258201
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ttnp-20180930_lab.xml EX-101.LAB 263198
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ttnp-20180930_pre.xml EX-101.PRE 282955
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-13341 | Film No.: 181183539
SIC: 2836 Biological Products, (No Diagnostic Substances)
Assistant Director 1